Pharma, Biotech and Pre-patent IP
Pharmaceutical and biotech firms hold molecular structures, trial protocols and synthesis routes that are worth billions long before a single patent is filed. They want AI that can mine decades of proprietary lab notes and failed trials to surface new formulations, but the cloud is barred because routing pre-patent assets through third-party processors opens a clear espionage and prior-disclosure vector. Mickai brings every retrieval and reasoning capability in-house, onto hardware the customer owns, under keys it holds. The data never leaves the building, no third party ever sees it, and the system runs independent of the internet and cloud vendors.
Heads of R&D, IP and information security at pharma and biotech firms responsible for protecting pre-patent assets.
Molecular structures, trial protocols and synthesis routes are billion-pound assets that risk espionage or prior disclosure the moment they touch the cloud before patents file.
Air-gapped retrieval and reasoning over decades of proprietary lab notes and failed trials, on hardware the customer owns under keys it holds.
New formulations are discovered and old failures are mined for insight with no early exposure of patentable assets, because what happens in the server room stays in the server room.
These architectural choices support control over the workflows in your deployment. Their benefits depend on configuration, integrations and operating practices. Review external connections, physical security, access and compliance responsibilities together.
Scope inference, extraction, retrieval and storage on infrastructure you control. Document and test any external connector, support channel or transfer before describing a workflow as zero-egress.
Workflows with local models, data and supporting services can continue offline. Live external email, calendars and other services need an approved connection or controlled import, with clear unavailable and pending states.
Map prompts, documents, indexes, logs and backups to their processing and storage locations. Local hosting supports control of location; access, retention and any transfers still need review.
Prepare and classify source records, preserve permissions and evaluate answers against the originals. Retrieval and model training are separate choices; agree data use and licences for each.
Compare hardware and licences alongside integration, power, administration, support, updates, evaluation and recovery. Measure cost at the required workload and quality before claiming savings.
Define who holds keys, who can administer the system and which actions need approval. Test denied requests, revoked access and audit records. Physical security, insider risk and incident response remain operational responsibilities.
Agree version selection, signed update procedures, rollback, data export and licence rights. Reassess requirements as software and obligations change; owning hardware does not remove maintenance or compliance work.
Review the requirements relevant to your organisation, jurisdiction and intended use with your responsible teams. Cloud services can be appropriate subject to applicable safeguards; on-premise deployment alone does not establish compliance or remove supplier responsibilities.
The kind of organisation this serves, named illustratively from public information to characterise the market. These are target profiles, not customers: Mickai has no relationship, engagement, trial, or endorsement with any of them.
The enterprise studios that lead in this sector, drawn from the eighteen that sit on the one sovereign substrate. Scope their local processing, operator-held keys and Open Audit Record coverage for the proposed deployment. Confirm availability and any external integrations before relying on a workflow.
Contract Review and Legal-Ops
Contract review and legal-ops over CDAs, licensing terms and collaboration agreements, all reasoned on-premises so deal-stage IP and obligations never touch an external processor.
Executive BI
Executive BI across pipeline, trial outcomes and portfolio risk, keeping board-level discovery intelligence inside the firm rather than on a vendor dashboard.
Compliance and Regulator Mode
Compliance and Regulator Mode aligned to GxP, 21 CFR Part 11 and EMA evidence, producing audit-ready records without exporting them; the customer keeps its own regulatory obligations.
Audit
Audit over lab notes, batch records and trial documentation, giving traceable retrieval across decades of proprietary and failed-trial data that stays air-gapped.
Sovereign Meeting Note-Taker
Sovereign meeting note-taker for research reviews, IP strategy sessions and investigator meetings, so sensitive discussion is captured on-premises and no third party ever sees it.
See all eighteen on the sovereign services catalogue.
Drug discovery and trial design are increasingly AI-driven, yet the most valuable corpus, a firm's own pre-patent chemistry and the institutional memory of what has already failed, is exactly the material that cannot be exposed to shared cloud infrastructure. That tension leaves a large, under-served demand for retrieval and reasoning that runs entirely inside the customer's own walls.
Measure value, cost and risk on hardware you control.
Firms can surface new formulations and reuse decades of failed-trial knowledge with no early exposure of patentable assets, removing the cross-border-transfer and third-party-processing friction that blocks cloud AI in this sector while displacing recurring cloud-inference spend; physical and insider controls remain yours.
Map the sovereign stack to your pharma, biotech and pre-patent ip estate.
Briefings are for organisations weighing a sovereign, on-premises deployment. Tell us about your estate and we will walk the pack, the regulatory crosswalk, and the deployment that fits your estate.